Abstract Details

Title APOE E4 Carrier Status Modulates Cognitive Outcome after Deep Brain Stimulation in Parkinson’s Disease Patients

Topic Movement Disorders

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 10-022

Objective To assess the role of APOE e4 carrier status on cognitive outcome of deep brain stimulation (DBS) surgery in Parkinson’s disease patients.

Background Apolipoprotein E e4 (APOE e4) allele carrier status, a well-known risk factor for Alzheimer’s disease, has also been associated with increased risk of cognitive decline in Parkinson’s disease. Previous reports of transcranial magnetic stimulation in elders without dementia found e4 carrier status modulates changes in network connectivity, suggesting that genotype plays a role in brain changes to stimulation. No study has examined the role of e4 carrier status on cognitive function after DBS.

Design/Methods Forty-seven PD patients who had undergone DBS at the NIH were genotyped on Illumina’s Neurochip and NeuroX custom-designed genotyping array. After quality control (call rates <95%, sex mismatches, heterozygous outliers), e4 carrier status was determined using SNPs rs7412 and rs429358. Patients with a pathogenic GBA mutation, previously reported to have a high risk for cognitive impairment were excluded. Multivariate linear regression was performed on the differences in pre- and 24-months post-operative cognitive scores (Mattis Dementia Rating Scale-2, Beck Depression Inventory, Weschler Adult Intelligence Scale, Repeatable Battery for the Assessment of Neuropsychological Status, Weschler Memory Scale, Boston Naming Test, Verbal Fluency) and APOE e4 carrier status, while controlling for sex, age at surgery, disease duration, and ethnicity.

Results Baseline cognitive and motor measures were not significantly different between the e4 carrier and non-carrier groups. After controlling for sex, age at surgery, disease duration, and ethnicity, the change in phenomic fluency score was negatively associated with APOE e4-carrier status (p<0.05).

Conclusions

We present for the first time the role of APOE e4 carrier status on the cognitive outcome of DBS. This study suggests that genotype plays a role in response to DBS and may contribute to variance in cognitive dysfunction after DBS.

Authors/Disclosures
Esther Yoon PRESENTER	Esther Yoon has nothing to disclose.
	No disclosure on file
	No disclosure on file
Debra J. Ehrlich, MD, FAAN (NIH/NINDS)	Dr. Ehrlich has nothing to disclose.

��ɫ��

��ɫ��